Latest News
Circassia Out-licenses ToleroTrans Organ Transplant Anti-Rejection Technology to Oxford Immunotec
12 August 2010
Circassia Achieves Positive Phase II Clinical Results With Ragweed Allergy T-cell Vaccine
Results Mark Third Successful Phase II Study With ToleroMune T-Cell Vaccines
12 February 2010
Circassia Appoints Cathrin Petty to its Board of Directors
08 February 2010
Circassia Extends its Clinical-Stage Portfolio With Phase II Trials of T-cell Vaccines Against House Dust Mite and Cat Allergies
19 January 2010
Did you know?
The average bed could be home to up to 1.5 million house dust mites